BIRC5 and breast cancer: For VGR-BC, due to the smaller dataset, heterogeneous OS outcome analysis did not achieve statistical significance, but the tendencies were similar to that showed in Figure 2B. The OS and DSS analysis supported the notion of poor prognosis for high BIRC5/survivin in the VGR-BC ER-negative groups (Table 2).